Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73583813" target="_blank" >RIV/61989592:15110/17:73583813 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1007/s11523-016-0469-y" target="_blank" >http://dx.doi.org/10.1007/s11523-016-0469-y</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11523-016-0469-y" target="_blank" >10.1007/s11523-016-0469-y</a>

Result language

angličtina

Original language name

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Original language description

Activating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part of the MAPK signaling pathway. This phase I/II study evaluated the safety and efficacy of refametinib plus gemcitabine in patients with advanced pancreatic cancer. Phase I comprised dose escalation, followed by phase II expansion. Refametinib and gemcitabine plasma levels were analyzed for pharmacokinetics. KRAS mutational status was determined from circulating tumor DNA.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Targeted Oncology

ISSN

1776-2596

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

1

Country of publishing house

FR - FRANCE

Number of pages

13

Pages from-to

97-109

UT code for WoS article

000393121700010

EID of the result in the Scopus database

—